
Commentary|Videos|December 13, 2024
Dr Rozenblit on Pembrolizumab Outcomes by TMB Status in HR+ Metastatic Breast Cancer
Author(s)Mariya Rozenblit, MD
Fact checked by: Ashling Wahner , Chris Ryan
Mariya Rozenblit, MD, discusses how genomic alterations and TMB influence the efficacy of immune checkpoint inhibitors in HR+ metastatic breast cancer.
Advertisement
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine, discusses findings from a study evaluating the prevalence of actionable genomic alterations and the predictive value of tumor mutational burden (TMB) for the efficacy of immune checkpoint inhibitors in patients with hormone receptor (HR)–positive, HER2-negative metastatic breast cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Unpacking the FDA Approvals That Reshaped Cancer Care in 2025
2
Nogapendekin Alfa Inbakicept Plus NK Cell Therapy Yields Strong OS Signal in Recurrent Glioblastoma
3
Immune-Targeting Vaccine Shows Promise Intercepting Cancer in Patients With Lynch Syndrome
4
FDA Grants Orphan Drug Designation to Gotistobart in Squamous NSCLC
5




































